Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects strong financial performance, with revenue and EPS guidance in line with expectations. The company shows positive developments in product and market strategies, including partnerships and re-entering networks, which are expected to drive growth. The Q&A reveals robust organic growth drivers and margin improvement. Despite weather impacts, management remains confident in recovery. The sentiment is slightly tempered by unclear responses on specific financial impacts, but overall, the outlook is optimistic, suggesting a positive stock price movement in the short term.
Key Financial Performance
Consolidated Revenues (Q4 2025) $2.81 billion, up 7.1% year-over-year. Growth driven by organic revenue growth (6.4%) and recent acquisitions.
Diagnostic Information Services Revenues (Q4 2025) Up 7.3% year-over-year. Growth attributed to organic growth in physician, hospital, and consumer channels, as well as recent acquisitions.
Total Volume (Q4 2025) Increased 8.5% year-over-year, with organic volume up 7.9%. Growth driven by Corewell Health and Fresenius Medical Care relationships.
Revenue Per Requisition (Q4 2025) Down 0.1% year-over-year. Lower revenue per requisition due to Corewell Health and Fresenius Medical Care relationships.
Reported Operating Income (Q4 2025) $386 million, 13.8% of revenues, compared to $361 million (13.8%) in Q4 2024. Increase due to organic revenue growth and acquisitions, offset by wage increases and start-up expenses.
Adjusted Operating Income (Q4 2025) $429 million, 15.3% of revenues, compared to $409 million (15.6%) in Q4 2024. Increase driven by organic revenue growth and acquisitions, offset by wage increases and start-up expenses.
Reported EPS (Q4 2025) $2.18, compared to $1.95 in Q4 2024. Increase due to higher operating income.
Adjusted EPS (Q4 2025) $2.42, compared to $2.23 in Q4 2024. Increase due to higher operating income.
Cash from Operations (Full Year 2025) $1.89 billion, compared to $1.33 billion in 2024. Increase driven by higher operating income, favorable working capital, tax benefits, and a one-time CARES Act tax credit.
Consumer-Initiated Testing Revenue (Full Year 2025) Nearly $250 million, exceeding 20% growth rate. Growth driven by questhealth.com and collaborations with wellness and wearables companies.
Advanced Diagnostics Revenue Growth (2025) Double-digit growth across several clinical areas, including cardiometabolic, autoimmune, brain health, oncology, and women's health.
Invigorate Program Cost Savings (2025) Achieved 3% annual cost savings and productivity improvements through automation, AI, and process enhancements.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Advanced Diagnostics: Delivered double-digit revenue growth in areas like cardiometabolic, autoimmune, brain health, oncology, and women's health. Innovations include Analyzer for autoimmune disorders and AD-Detect for Alzheimer's.
Consumer-Initiated Testing: Expanded questhealth.com to offer over 150 tests, including the Elite Health profile. Achieved over 20% revenue growth, generating nearly $250 million in 2025.
Oncology Innovations: Launched Haystack MRD test for colorectal cancer and flow MRD test for myeloma, enabling less invasive and more sensitive diagnostics.
Geographic Expansion: Achieved high single-digit organic revenue growth in the physician channel due to increased health plan access and geographic expansion.
Collaborations: Scaled lab testing for Fresenius Medical Care's dialysis centers and expanded Co-Lab solutions to Corewell Health's 21 hospitals, expecting $1 billion in annual revenues in 2026.
Cost Savings and Productivity: Achieved 3% annual cost savings through the Invigorate program. Deployed automation and AI to streamline lab processes and improve customer experience.
AI and Automation: Implemented AI tools to reduce logistics calls by 50% and optimize courier transportation times. Deployed automated sample processing and digital diagnostic systems in labs.
PAMA Legislation: Secured a 1-year delay in PAMA rate cuts, providing short-term relief but highlighting the need for structural reforms.
Hospital Partnerships: Finalized a joint venture with Corewell Health, constructing a state-of-the-art lab in Michigan to serve the state by 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
PAMA Legislation: The structural flaws in PAMA legislation, including reliance on self-reported data from a small percentage of labs, have led to excessive rate cuts in the past. Although a one-year delay in rate cuts has been enacted, the underlying issues remain unresolved, posing risks to future payment rates and financial stability.
Severe Weather Impact: Severe weather in January 2026 has created a significant headwind, impacting operations and potentially affecting revenue and performance in the first quarter of 2026.
Project Nova Investment: The multiyear Project Nova initiative to modernize the order-to-cash process is expected to dilute EPS by approximately $0.25 in 2026 due to increased investment spending.
Corewell Health Co-Lab Margins: The Co-Lab relationship with Corewell Health, while adding $250 million in organic revenue, is expected to operate at low single-digit margins in 2026, potentially impacting overall profitability.
Tax Rate Increase: The adjusted effective tax rate is expected to increase by approximately 100 basis points in 2026 compared to 2025, which could affect net earnings.
One-Time Benefits in 2025: The 2025 financial performance benefited from one-time factors such as tax credits and favorable working capital timing, which will not recur in 2026, potentially impacting year-over-year comparisons.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Revenues for 2026 are expected to be between $11.7 billion and $11.82 billion, representing a growth rate of 6% to 7.1%. This does not include any contribution from prospective M&A.
Earnings Per Share (EPS): Reported EPS is expected to be in the range of $9.45 to $9.65, and adjusted EPS in the range of $10.50 to $10.70.
Cash Flow and Capital Expenditures: Cash from operations is expected to be approximately $1.75 billion. Capital expenditures are projected to be approximately $550 million.
Operating Margin: Operating margin is expected to expand versus the prior year.
Co-Lab Solutions Revenue: The Co-Lab relationship with Corewell Health is expected to add approximately $250 million in organic revenue at low single-digit margins in 2026.
Project Nova: The multiyear initiative to modernize the order-to-cash process is expected to result in approximately $0.25 of EPS dilution related to increased investment spend versus 2025.
Tax Rate: The adjusted effective tax rate is expected to increase approximately 100 basis points in 2026 compared to 2025.
Seasonality and Weather Impact: The seasonality of the business is expected to align with pre-COVID patterns, with severe weather in January 2026 creating a headwind factored into the guidance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the underlying growth drivers for 2026?
A:The growth drivers include strong organic growth, uplift in Alzheimer's portfolio of tests, autoimmune testing, diabetes, cardiovascular testing (including advanced testing like Cardio IQ), consumer segment growth through partnerships (e.g., WHOOP, Oura, Function Health), and re-entering networks in key states like Nevada, Colorado, Georgia, and Virginia.
Q:How is the company addressing the weather impact in Q1?
A:The company experienced a tough January due to weather but expects recovery throughout the quarter. Systems are in place to track and remind patients of missed appointments, and strong utilization in early January provides confidence in recovery.
Q:What are the moving pieces on margins for 2026?
A:Operating margin is expected to increase in 2026. Factors include Corewell's $250 million revenue at low single-digit margins, strong organic volumes, stable pricing, less dilution from Haystack, and incremental expenses from Project Nova ($0.25). Seasonality is expected to be similar to pre-COVID patterns.
Q:What is the competitive environment and share gain expectations for 2026?
A:The company expects share gains, particularly from re-entering networks with Elevance and Centerra. Strengths include national coverage, a large sales force, and inroads against hospital outreach and physician office labs. The market share of Quest and its nearest competitor is less than 30%.
Q:What is the impact of health exchanges and organic volume growth in Q4?
A:Health exchanges are modeled to have a 30 basis point impact on revenue growth. Enrollment trends are better than expected. Organic volume growth in Q4 was 4.1% excluding Fresenius and Corewell, with a 3% organic revenue per requisition lift.
Q:What is the company's stance on PAMA and the RESULTS Act?
A:The company supports the RESULTS Act to address flaws in the original PAMA methodology. It is prepared to report data but emphasizes the need for broader participation from other labs. The Act proposes using a third-party database for accurate market-based pricing.
Q:What are the dynamics and growth expectations for consumer testing?
A:Consumer testing is growing strongly, driven by partnerships with wearable companies and wellness providers. Questhealth.com is a $100 million run-rate business, growing at 35%. The segment has an attractive margin profile due to cash pay and no denials. Long-term CAGR is expected to exceed 20%.
Q:What is the margin opportunity and ramp for Corewell and Fresenius?
A:Corewell is expected to generate $250 million in 2026 at low single-digit margins, improving to low teens by 2027. Fresenius is expected to reach or exceed the company average margin by the end of 2026.
Q:What are the updates on oncology initiatives like Haystack and MRD tests?
A:Haystack has received reimbursement and is progressing with Medicare Advantage and commercial payers. The flow cytometry-based MRD test offers competitive sensitivity, faster turnaround (3 days), and lower cost compared to sequencing-based tests. Partnerships with GRAIL and Guardant are included in guidance.
Q:How is the company monetizing its data and exploring AI opportunities?
A:The data business is growing double digits, serving pharmaceutical companies, payers, and public health agencies. Partnerships with AI companies are being explored to provide health insights and population health analytics.
Q:What is the impact of re-entering networks with Elevance and Centerra?
A:Re-entering networks with Elevance in key states and Centerra's health plan is expected to drive share gains over a three-year ramp period.
Q:What is the impact of weather on Q1 2026 guidance?
A:The weather impact in January was significant but is embedded in the guidance. Recovery is expected in the remaining months of the quarter, with strong underlying utilization trends.
Q:What are the revenue per requisition growth assumptions for 2026?
A:Revenue per requisition is impacted by high-volume, lower-revenue businesses like Fresenius. Excluding Fresenius and Corewell, revenue per requisition growth is consistent with prior trends, driven by stable pricing and increased test per requisition.
Q:Review of Unclear Management Responses
A:Management avoided providing specific quantifications for certain impacts, such as the exact financial impact of Fresenius and Corewell setup costs in Q4, and did not provide detailed guidance on revenue per requisition growth for 2026. Additionally, while optimistic about the RESULTS Act, management did not provide a clear timeline for its potential enactment.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CMS
Co Lab
Congress
Corewell Health
Haystack MRD
Lab solution
Michigan
Project Nova
Quest Diagnostics
approach
benefit payroll
biomarker
cancer
category
channel diagnostics
channel revenue
collaboration
consumer channel
diagnosis
disorder
example
expertise
flow
health care
implementation
industry
innovation
lab self
legislation
logistics
organization
payroll cycle
quality productivity
rate cut
reminder
state
use
volume requisition
week
wellness
DGX Transcript
Quest Diagnostics Incorporated (DGX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call Transcript
Positive2-10
The earnings call summary reflects strong financial performance, with revenue and EPS guidance in line with expectations. The company shows positive developments in product and market strategies, including partnerships and re-entering networks, which are expected to drive growth. The Q&A reveals robust organic growth drivers and margin improvement. Despite weather impacts, management remains confident in recovery. The sentiment is slightly tempered by unclear responses on specific financial impacts, but overall, the outlook is optimistic, suggesting a positive stock price movement in the short term.
Quest Diagnostics Incorporated (DGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Quest Diagnostics Incorporated (DGX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-2
DGX Slides
DGX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
